دورية أكاديمية
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
| العنوان: | Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters |
|---|---|
| المؤلفون: | Tostanoski, Lisa H., Wegmann, Frank, Martinot, Amanda J., Loos, Carolin, McMahan, Katherine, Mercado, Noe B., Yu, Jingyou, Chan, Chi N., Bondoc, Stephen, Starke, Carly E., Nekorchuk, Michael, Busman-Sahay, Kathleen, Piedra-Mora, Cesar, Wrijil, Linda M., Ducat, Sarah, Custers, Jerome, Atyeo, Caroline, Fischinger, Stephanie, Burke, John S., Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Jacob-Dolan, Catherine, Lin, Zijin, Mahrokhian, Shant H., Nampanya, Felix, Nityanandam, Ramya, Pessaint, Laurent, Porto, Maciel, Ali, Vaneesha, Benetiene, Dalia, Tevi, Komlan, Andersen, Hanne, Lewis, Mark G., Schmidt, Aaron G., Lauffenburger, Douglas A., Alter, Galit, Estes, Jacob D., Schuitemaker, Hanneke, Zahn, Roland, Barouch , Dan H. |
| المصدر: | reponame:Expeditio Repositorio Institucional UJTL ; instname:Universidad de Bogotá Jorge Tadeo Lozano |
| بيانات النشر: | Nature medicine |
| سنة النشر: | 2020 |
| المجموعة: | Expeditio - Repositorio Institucional Universidad de Bogotá Jorge Tadeo Lozano (UTADEO) |
| مصطلحات موضوعية: | Ad26 vaccine, SARS-CoV-2, Clinical disease, Síndrome respiratorio agudo grave, COVID-19, Coronavirus |
| الوصف: | Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death1–4. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters5–7 and nonhuman primates8–10 have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates11–13. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 23 páginas; application/pdf |
| اللغة: | English |
| تدمد: | 1546-170X |
| العلاقة: | https://doi.org/10.1038/s41591-020-1070-6Test; http://hdl.handle.net/20.500.12010/13448Test |
| DOI: | 10.1038/s41591-020-1070-6 |
| الإتاحة: | https://doi.org/20.500.12010/13448Test https://doi.org/10.1038/s41591-020-1070-6Test https://hdl.handle.net/20.500.12010/13448Test |
| حقوق: | info:eu-repo/semantics/openAccess ; Abierto (Texto Completo) |
| رقم الانضمام: | edsbas.BB9BA34B |
| قاعدة البيانات: | BASE |
| تدمد: | 1546170X |
|---|---|
| DOI: | 10.1038/s41591-020-1070-6 |